Compounds > carbapenems
Page last updated: 2024-09-04

carbapenems and tazobactam

carbapenems has been researched along with tazobactam in 71 studies

Compound Research Comparison

Studies
(carbapenems)		Trials
(carbapenems)		Recent Studies (post-2010)
(carbapenems)		Studies
(tazobactam)		Trials
(tazobactam)		Recent Studies (post-2010) (tazobactam)
7,3551475,2771,327153694

Protein Interaction Comparison

ProteinTaxonomycarbapenems (IC50)tazobactam (IC50)
Beta-lactamase Klebsiella pneumoniae0.08
Beta-lactamase Escherichia coli0.01
Beta-lactamase Citrobacter freundii0.096
Beta-lactamase Citrobacter gillenii0.04
Beta-lactamase Shouchella clausii0.004
Beta-lactamase Burkholderia cenocepacia0.5
Beta-lactamase Pseudomonas aeruginosa0.06
Beta-lactamase Pseudomonas aeruginosa2
B2 bradykinin receptorCavia porcellus (domestic guinea pig)4.8
Beta-lactamaseStaphylococcus aureus0.5
Beta-lactamaseBacillus licheniformis0.51
Beta-lactamaseEscherichia coli K-120.25
Beta-lactamaseCitrobacter freundii0.93
Beta-lactamaseEnterobacter cloacae1.3748
Beta-lactamase SHV-1Escherichia coli0.222
Beta-lactamase SHV-1Klebsiella pneumoniae0.11
Beta-lactamase OXA-1Escherichia coli4.8
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)0.83
Cytochrome P450 2B6Homo sapiens (human)0.11
Beta-lactamasePseudomonas aeruginosa PAO12.51
Beta-lactamase TEMEscherichia coli0.0828
Beta-lactamaseMorganella morganii0.19
Beta-lactamase Salmonella enterica subsp. enterica serovar Westhampton0.0022
Beta-lactamase Pseudomonas aeruginosa2
Beta-lactamase Enterobacter cloacae0.03
Class D beta-lactamaseBrachyspira pilosicoli0.16
Beta-lactamase Pseudomonas luteola0.04
Beta-lactamase Escherichia coli0.24
Beta-lactamase Serratia fonticola6.9
Beta-lactamase Enterobacter cloacae0.06
Beta-lactamase Escherichia coli0.002
Carbapenem-hydrolyzing beta-lactamase KPCKlebsiella pneumoniae0.372

Research

Studies (71)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (5.63)18.2507
2000's5 (7.04)29.6817
2010's23 (32.39)24.3611
2020's39 (54.93)2.80

Authors

AuthorsStudies
Livermore, DM; Yuan, M1
Blumer, JL; Bonafede, ME1
Babini, GS; Bates, J; Livermore, DM; Palepou, MF; Woodford, N1
Allerberger, F; Feierl, G; Hirschl, A; Krause, R; Mittermayer, H; Reisinger, EC; Wendelin, I1
Blosser-Middleton, RS; Ge, Y; Karlowsky, JA; Sahm, DF; Wikler, MA1
Fraser, A; Leibovici, L; Paul, M; Yahav, D1
Correia, A; Domingues, MR; Domingues, P; Fonseca, F; Henriques, I; Saavedra, MJ; Samyn, B; Sarmento, AC; van Beeumen, J1
Friedland, I; Kaniga, K; Ketter, N; Lee, M; Lobo, SM; Niederman, M; Prokocimer, P; Réa-Neto, A; Schroeder, E1
Gospodarek, E; Jachna-Sawicka, K1
Gast, C; Ketter, N; Kollef, MH; Merchant, S; Nathwani, D; Quintana, A1
Chang, WC; Chen, CP; Chen, TL; Cho, WL; Fung, CP; Kuo, SC; Lee, YT; Siu, LK1
Bonnin, RA; Lecuyer, H; Nordmann, P; Poirel, L; Potron, A; Zahar, JR1
Bethel, CR; Bonnet, R; Bonomo, RA; Distler, AM; Endimiani, A; Hujer, AM; Hujer, KM; Papp-Wallace, K; Shyr, T; Taracila, M; Thomson, JM1
Bernusset, S; Cattoen, C; Cuzon, G; Naas, T; Nordmann, P1
Antunes, NT; Frase, H; Toth, M; Vakulenko, SB; Vakulenko, V1
Falagas, ME; Ikawa, K; Tansarli, GS; Vardakas, KZ1
Chai, LY; Chee, YL; Chng, WJ; Ding, Y; Hsu, LY; Jin, J; Lee, YM; Poon, LM; Tan, LK1
Abbas, S; Dortet, L; Nordmann, P; Oueslati, S; Poirel, L1
Boyd, D; Carpenter, M; Desruisseau, A; Janecko, N; Mangat, CS; Martz, SL; Mulvey, MR; Reid-Smith, RJ1
Chen, Y; Gao, W; Li, X; Ouyang, W; Wei, J; Wen, Z; Xue, H1
Mikamo, H; Sugimoto, N; Yamagishi, Y1
Lavigne, JP; Meiller, E; Merens, A; Nicolas-Chanoine, MH; Pantel, A; Robert, J1
Abbo, LM; Adachi, J; Aitken, SL; Araos, R; Arias, CA; Bonomo, RA; Jain, R; Lichtenberger, PN; Miller, WR; Munita, JM; Nigo, M; Perez, F; Rakita, R; Rosa, R; Shelburne, S; Shimose, LA; Tran, TT; Wanger, A1
Alp, E; Çetin, M; Elmali, F; Kaynar, L; Kürkçüoglu, CA; Metan, G; Yozgat, N1
Arai, K; Kato, M; Matsuoka, T; Mori, T; Ohashi, K; Shinoda, Y; Yoshida, S; Yoshimura, T1
Bertrand, X; Bouiller, K; Bouxom, H; Fournier, D; Hocquet, D1
Dubois, V; Jayol, A; Kieffer, N; Nordmann, P; Ortiz De La Rosa, JM; Poirel, L1
Hsu, AJ; Tamma, PD1
Aitken, E; Gould, IM; Hijazi, K; Joshi, C; Oggioni, MR; Zamudio, R1
Avery, LM; Nicolau, DP; Sutherland, CA1
Li, J; Ma, W; Sun, S; Wang, D; Yu, C1
Busch, DH; Katchanov, J; Lahmer, T; Rothe, K; Schmid, RM; Schneider, J; Spinner, CD; Wantia, N; Waschulzik, B1
Gatermann, SG; Körber-Irrgang, B; Korte-Berwanger, M; Kresken, M; Pfennigwerth, N; Seifert, H1
Bassetti, M; Battaglini, D; Giacobbe, DR; Pelosi, P; Vena, A1
Bassetti, M; Giacobbe, DR; Pelosi, P; Robba, C; Vena, A1
Cisera, K; Hughes, C; Rogers, B; Taylor, L; Xie, O1
Arend, LNVS; Bail, L; Ito, CAS; Nogueira, KDS; Tuon, FF2
Bernardi, M; Castagna, A; Castiglion, B; Ciceri, F; Clerici, D; Corti, C; Farina, F; Giglio, F; Greco, R; Liberatore, C; Lorentino, F; Mastaglio, S; Oltolini, C; Pavesi, F; Peccatori, J; Ripa, M; Scarpellini, P; Tassan Din, C1
Bragantini, D; Carrara, E; Cattaneo, P; Chiamenti, M; Ellis, S; Franceschi, F; Giske, CG; Lodise, T; Menchinelli, G; Piddock, LJV; Righi, E; Sanguinetti, M; Savoldi, A; Scudeller, L; Tacconelli, E1
Alcalde-Rico, M; Arias, CA; García, P; Khan, A; Martínez, JRW; Miller, WR; Moreno, MV; Munita, JM; Olivares-Pacheco, J; Rivas, L; Rojas, P; Wozniak, A1
Caldwell, B; Hamprecht, A; Henriksen, AS; Longshaw, C; Thelen, P; Yamano, Y1
Albur, M; Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR1
Carratalà, J; Cuervo, G; González Laguna, M; Llop Talaveron, J; Padullés, A; Pérez-Recio, S; Ronda, M; Soldevila-Boixader, L; Tubau Quintano, MF1
Ang, B; Ang, LW; Chua, BH; Heng, ST; Lee, TH; Lin, R; Lye, DC; Ng, TM; Quek, J; Tan, SH; Tay, HL; Teng, CB; Yap, MY; Young, BE1
Annane, D; Bonten, MJM; Carneiro, J; Deja, M; Estevez, F; Harbarth, S; Jereb, M; Jorens, PG; Lawrence, C; Rothbart, A; Schedler, D; Seme, K; Šifrer, F; Spöhr, F; Tomič, V; van Duijn, PJ; Verbrugghe, W1
Ju, YG; Lee, HJ; Lee, MG; Sohn, JW; Yim, HS; Yoon, YK1
Cruz-López, F; Garza-González, E; Maldonado-Garza, HJ; Martínez-Meléndez, A; Morfin-Otero, R; Rodriguez-Noriega, E1
Birgy, A; Bonacorsi, S; Courroux, C; Danjean, M; Gits-Muselli, M; Hobson, CA; Monjault, A1
Carvalhaes, CG; Castanheria, M; Duncan, LR; Mendes, RE; Sader, HS1
Deligios, M; Fiamma, M; Paglietti, B; Rubino, S; Sacarlal, J; Santona, A; Simbine, SE; Sumbana, JJ; Taviani, E; Zimba, T1
Bellini, R; Ciapina, LP; Dardenne, LE; de Vasconcelos, ATR; Guedes, IA; Nicolás, MF1
Gehlot, P; P, H1
Haines, RR; Hammer, KA; Putsathit, P; Tai, AS1
Dong, L; Feng, J; Geng, H; Gu, S; He, C; Hou, G; Ji, T; Kang, W; Lai, J; Li, Y; Li, Z; Pang, D; Wang, Y; Zhao, L; Zhu, X; Zhu, Y1
Guery, B; Jacot, D; Papadimitriou-Olivgeris, M1
Maseda, E; Suárez de la Rica, A1
Assanelli, AA; Bernardi, M; Carletti, S; Carrabba, MG; Castagna, A; Ciceri, F; Clerici, D; Corti, C; Erbella, F; Farina, F; Galli, L; Giglio, F; Greco, R; Liberatore, C; Lorentino, F; Lugli, AP; Lupo Stanghellini, MT; Mancini, N; Mastaglio, S; Nitti, R; Oltolini, C; Peccatori, J; Poli, A; Ripa, M; Ruggeri, A; Scarpellini, P; Tassan Din, C; Xue, E1
Gill, CM; Nicolau, DP3
Dalğıç, D; Kandemir, T; Nağıyev, T; Üçkayabaşı, A1
Carvalho, TN; Deglmann, RC; França, PHC; Hille, D; Kobs, VC; Melo, LH1
Ballesta, S; López, CE; López-Cerero, L; Pascual, A; Rojo-Martin, MD; Sánchez-Yebra, W1
Banjara, MR; Devkota, MD; Pokhrel, BM; Sharma, S1
Bogiel, T; Grabowska, M; Sękowska, A1
Chau, RWY; Chen, WT; DeRyke, CA; Ip, M; Karlowsky, JA; Khan, TK; Leung, SWM; Lob, SH; Motyl, MR; Sahm, DF; Seto, WH; Wong, QW; Woo, PCY; Young, K1
Chen, TY; Hsu, CK; Lai, CC; Shih, SC; Tang, HJ; Weng, TS1
Hsueh, PR; Ko, WC; Lee, YL1
Fujimori, T; Hagiya, H; Higashikage, A; Iio, K; Kakehi, A; Minabe, H; Okura, M; Otsuka, F; Yokoyama, Y1
Chen, WT; Cheng, MH; Hsieh, TC; Karlowsky, JA; Lu, HC; Motyl, MR; Sahm, DF; Siddiqui, F; Wise, MG; Young, K1

Reviews

10 review(s) available for carbapenems and tazobactam

ArticleYear
Role of newer broad-spectrum beta-lactam and fluoroquinolone antibiotics in children.
    Advances in pediatric infectious diseases, 1996, Volume: 12

    Topics: Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Carbapenems; Cephalosporins; Child; Child, Preschool; Clavulanic Acid; Clavulanic Acids; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Fluoroquinolones; Humans; Molecular Structure; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam; Ticarcillin

1996
Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials.
    The Journal of antimicrobial chemotherapy, 2006, Volume: 57, Issue:2

    Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefepime; Cephalosporins; Enzyme Inhibitors; Fever; Humans; Neutropenia; Penicillanic Acid; Penicillins; Quality Assurance, Health Care; Randomized Controlled Trials as Topic; Tazobactam; Treatment Outcome

2006
Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:2

    Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactam Resistance; Carbapenems; Drug Administration Schedule; Humans; Infusions, Intravenous; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome

2013
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
    Journal of the Pediatric Infectious Diseases Society, 2019, Jul-01, Volume: 8, Issue:3

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Boronic Acids; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Meropenem; Tazobactam

2019
The role of new antimicrobials for Gram-negative infections in daily clinical practice.
    Current opinion in infectious diseases, 2020, Volume: 33, Issue:6

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactams; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Imipenem; Microbial Sensitivity Tests; Polymyxins; Sisomicin; Tazobactam; Tetracyclines

2020
Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors?
    Current opinion in infectious diseases, 2020, Volume: 33, Issue:6

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ceftaroline; Ceftazidime; Cephalosporins; Cyclooctanes; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Public Health; Sepsis; Tazobactam

2020
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
    International journal of antimicrobial agents, 2021, Volume: 57, Issue:5

    Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Fosfomycin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; In Vitro Techniques; Microbial Sensitivity Tests; Polymyxins; Rifampin; Tazobactam; Tobramycin

2021
Efficacy and
    Frontiers in cellular and infection microbiology, 2022, Volume: 12

    Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Tazobactam

2022
Controversies in the management of ESBL-producing Enterabacterales. Clinical Implications.
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2022, Volume: 35 Suppl 3

    Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Cephalosporins; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin, Tazobactam Drug Combination; Tazobactam

2022
Comparing novel antibiotics and carbapenems for complicated intra-abdominal infections: a systematic review and meta-analysis of randomized controlled trials.
    International journal of antimicrobial agents, 2023, Volume: 62, Issue:2

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Drug Combinations; Humans; Intraabdominal Infections; Randomized Controlled Trials as Topic; Tazobactam

2023

Trials

2 trial(s) available for carbapenems and tazobactam

ArticleYear
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
    Current medical research and opinion, 2008, Volume: 24, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Carbapenems; Cross Infection; Doripenem; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Prospective Studies; Tazobactam; Treatment Outcome

2008
The effects of antibiotic cycling and mixing on acquisition of antibiotic resistant bacteria in the ICU: A post-hoc individual patient analysis of a prospective cluster-randomized crossover study.
    PloS one, 2022, Volume: 17, Issue:5

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Cross-Over Studies; Gram-Negative Bacteria; Humans; Intensive Care Units; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Tazobactam

2022

Other Studies

59 other study(ies) available for carbapenems and tazobactam

ArticleYear
Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.
    The Journal of antimicrobial chemotherapy, 1996, Volume: 38, Issue:3

    Topics: Ampicillin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Clavulanic Acid; Clavulanic Acids; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Humans; Intensive Care Units; Klebsiella; Klebsiella Infections; Microbial Sensitivity Tests; Monobactams; Penicillanic Acid; Piperacillin; Tazobactam

1996
Carbapenemase-producing Pseudomonas aeruginosa in UK.
    Lancet (London, England), 1998, Aug-15, Volume: 352, Issue:9127

    Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Enzyme Inhibitors; Gentamicins; Humans; Imipenem; Meropenem; Metalloproteins; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; United Kingdom

1998
In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Wiener klinische Wochenschrift, 1999, Jul-30, Volume: 111, Issue:14

    Topics: Acinetobacter; Anti-Bacterial Agents; Austria; beta-Lactam Resistance; Carbapenems; Cephalosporins; Enterobacteriaceae; Humans; Imipenem; In Vitro Techniques; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonadaceae; Tazobactam; Thienamycins

1999
In vitro antimicrobial activity of doripenem, a new carbapenem.
    Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:4

    Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Cephalosporins; Doripenem; Drug Therapy, Combination; Enterobacteriaceae; Gram-Positive Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Tazobactam

2004
Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:12

    Topics: Aztreonam; beta-Lactamases; Carbapenems; Catalysis; Cephalosporins; Clavulanic Acid; Electrophoresis, Polyacrylamide Gel; Escherichia coli; Hydrolysis; Kinetics; Molecular Weight; Penicillanic Acid; Penicillins; Recombinant Proteins; Serratia; Sulbactam; Tazobactam

2007
[Evaluation of occurrence of Alcaligenes faecalis in clinical samples of patients of the university hospital in Bydgoszcz].
    Medycyna doswiadczalna i mikrobiologia, 2009, Volume: 61, Issue:1

    Topics: Alcaligenes faecalis; Carbapenems; Drug Resistance, Bacterial; Environmental Microbiology; Environmental Monitoring; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Suppuration; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination; Urine

2009
Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators.
    Critical care (London, England), 2010, Volume: 14, Issue:3

    Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Clinical Trials, Phase III as Topic; Doripenem; Female; Health Resources; Humans; Imipenem; Length of Stay; Male; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; Prospective Studies; Randomized Controlled Trials as Topic; Tazobactam; Treatment Outcome

2010
Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:8

    Topics: Acinetobacter; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; DNA Transposable Elements; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Promoter Regions, Genetic; Recombination, Genetic; Sequence Analysis, DNA; Species Specificity; Tazobactam

2010
Carbapenem-hydrolyzing GES-type extended-spectrum beta-lactamase in Acinetobacter baumannii.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:1

    Topics: Acinetobacter baumannii; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Clavulanic Acid; Escherichia coli; Microbial Sensitivity Tests; Models, Genetic; Molecular Sequence Data; Penicillanic Acid; Polymerase Chain Reaction; Tazobactam

2011
Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:7

    Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Clavulanic Acid; Enzyme Inhibitors; Escherichia coli Proteins; Kinetics; Meropenem; Molecular Dynamics Simulation; Molecular Structure; Penicillanic Acid; Spectrometry, Mass, Electrospray Ionization; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sulbactam; Tazobactam; Thienamycins

2011
First identification of blaIMI-1 in an Enterobacter cloacae clinical isolate from France.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:3

    Topics: Adult; Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Enterobacter cloacae; Enterobacteriaceae Infections; France; Humans; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pneumonia, Ventilator-Associated; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Tazobactam

2012
Class A carbapenemase FPH-1 from Francisella philomiragia.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6

    Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Doripenem; Ertapenem; Escherichia coli; Francisella; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam; Thienamycins

2012
Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital.
    Singapore medical journal, 2012, Volume: 53, Issue:11

    Topics: Academic Medical Centers; Adult; Bacteremia; Carbapenems; Ceftazidime; Drug Resistance, Multiple; Febrile Neutropenia; Female; Gram-Negative Bacteria; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Prevalence; Prospective Studies; Risk Factors; Sepsis; Singapore; Tazobactam; Treatment Outcome; Universities

2012
Genetic and Biochemical Characterization of FRI-1, a Carbapenem-Hydrolyzing Class A β-Lactamase from Enterobacter cloacae.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:12

    Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Clavulanic Acid; Cloning, Molecular; Drug Resistance, Multiple, Bacterial; Enterobacter cloacae; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillanic Acid; Plasmids; Sequence Homology, Amino Acid; Tazobactam

2015
Characterization of VCC-1, a Novel Ambler Class A Carbapenemase from Vibrio cholerae Isolated from Imported Retail Shrimp Sold in Canada.
    Antimicrobial agents and chemotherapy, 2016, Jan-11, Volume: 60, Issue:3

    Topics: Amino Acid Sequence; Animals; Aztreonam; Bacterial Proteins; Base Sequence; beta-Lactamases; Canada; Carbapenems; Cephalosporins; Clavulanic Acid; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Penaeidae; Penicillanic Acid; Penicillins; Seafood; Sequence Alignment; Sequence Analysis, DNA; Tazobactam; Vibrio cholerae

2016
Clinical characteristics and antimicrobial patterns in complicated intra-abdominal infections: a 6-year epidemiological study in southern China.
    International journal of antimicrobial agents, 2016, Volume: 47, Issue:3

    Topics: Anti-Bacterial Agents; Carbapenems; China; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enterococcus faecalis; Epidemiologic Studies; Escherichia coli; Female; Gentamicins; Humans; Intraabdominal Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Treatment Outcome

2016
Proposed breakpoint of piperacillin/tazobactam against extended spectrum β-lactamases producing bacteria in bacteremia.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2017, Volume: 23, Issue:1

    Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Bacteria; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Enterobacteriaceae; Female; Humans; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Tazobactam

2017
Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
    BMC infectious diseases, 2017, 01-17, Volume: 17, Issue:1

    Topics: Algorithms; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Tazobactam; Thienamycins; Ticarcillin

2017
Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, 07-01, Volume: 65, Issue:1

    Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Female; Humans; Male; Middle Aged; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam

2017
A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre.
    Le infezioni in medicina, 2017, Mar-01, Volume: 25, Issue:1

    Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Cross Infection; Febrile Neutropenia; Guidelines as Topic; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam; Teicoplanin; Tertiary Care Centers; Treatment Outcome; Turkey; Vancomycin

2017
Effectiveness of a Computer-facilitated, Pharmacist-driven Antimicrobial Stewardship Program for Infection Management.
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2017, Volume: 137, Issue:5

    Topics: Anti-Bacterial Agents; Carbapenems; Computer Systems; Cost Savings; Databases, Factual; Drug Monitoring; Drug Utilization; Drug Utilization Review; Humans; Infection Control; Methicillin-Resistant Staphylococcus aureus; Monitoring, Physiologic; Penicillanic Acid; Pharmacists; Piperacillin; Tazobactam

2017
Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae?
    International journal of antimicrobial agents, 2018, Volume: 52, Issue:1

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam; Urinary Tract Infections

2018
Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:1

    Topics: Amino Acid Substitution; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2019
Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    International journal of antimicrobial agents, 2019, Volume: 53, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Drug Resistance, Bacterial; Female; Hospitals; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Piperacillin, Tazobactam Drug Combination; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Scotland; Tazobactam; Whole Genome Sequencing

2019
Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.
    Journal of medical microbiology, 2019, Volume: 68, Issue:6

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Drug Synergism; Fosfomycin; Humans; Meropenem; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tobramycin; United States

2019
In vitro interaction of various antibiotic combinations recommended by Chinese consensus statement against carbapenems-resistant Pseudomonas aeruginosa.
    Letters in applied microbiology, 2019, Volume: 69, Issue:3

    Topics: Anti-Bacterial Agents; Aztreonam; Carbapenems; Cefoperazone; Ceftazidime; China; Cross Infection; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2019
Antimicrobial resistance of bacteraemia in the emergency department of a German university hospital (2013-2018): potential carbapenem-sparing empiric treatment options in light of the new EUCAST recommendations.
    BMC infectious diseases, 2019, Dec-30, Volume: 19, Issue:1

    Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Drug Resistance, Bacterial; Emergency Service, Hospital; Enterobacteriaceae; Germany; Hospitals, University; Humans; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Retrospective Studies; Staphylococcus aureus; Tazobactam; Treatment Outcome

2019
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
    International journal of antimicrobial agents, 2020, Volume: 55, Issue:6

    Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cephalosporins; Cross Infection; Drug Resistance, Multiple, Bacterial; Germany; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Middle Aged; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2020
Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection.
    Annals of clinical microbiology and antimicrobials, 2020, Nov-30, Volume: 19, Issue:1

    Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteremia; Carbapenems; Ceftazidime; Ceftriaxone; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Tazobactam

2020
The activity of ceftazidime/avibactam against carbapenem-resistant
    Infectious diseases (London, England), 2021, Volume: 53, Issue:5

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2021
The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
    International journal of antimicrobial agents, 2021, Volume: 57, Issue:6

    Topics: Adult; Aged; Allografts; Anti-Bacterial Agents; Autografts; Azabicyclo Compounds; Bacteremia; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Retrospective Studies; Tazobactam; Treatment Outcome; Young Adult

2021
Activity of imipenem-relebactam and ceftolozane-tazobactam against carbapenem-resistant Pseudomonas aeruginosa and KPC-producing Enterobacterales.
    Diagnostic microbiology and infectious disease, 2022, Volume: 102, Issue:1

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam

2022
Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa.
    Antimicrobial agents and chemotherapy, 2022, 01-18, Volume: 66, Issue:1

    Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2022
In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany.
    Journal of global antimicrobial resistance, 2022, Volume: 28

    Topics: Anti-Bacterial Agents; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Tazobactam

2022
Comparative bactericidal activity of representative β-lactams against Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa.
    The Journal of antimicrobial chemotherapy, 2022, 04-27, Volume: 77, Issue:5

    Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Ceftazidime; Cephalosporins; Escherichia coli; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Monobactams; Piperacillin; Pseudomonas aeruginosa; Tazobactam

2022
Ceftolozane/tazobactam for difficult-to-treat Gram-negative infections: A real-world tertiary hospital experience.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:7

    Topics: Adult; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tazobactam; Tertiary Care Centers

2022
Sustaining Antimicrobial Stewardship in a High-Antibiotic Resistance Setting.
    JAMA network open, 2022, 05-02, Volume: 5, Issue:5

    Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Cohort Studies; Drug Resistance, Microbial; Humans; Piperacillin; Prospective Studies; Tazobactam

2022
In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii.
    Scientific reports, 2022, 05-09, Volume: 12, Issue:1

    Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Carbapenems; Cephalosporins; Colistin; Drug Combinations; Drug Synergism; Humans; Meropenem; Microbial Sensitivity Tests; Rifampin; Tazobactam; Tigecycline

2022
Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:11

    Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Humans; Imipenem; Meropenem; Tazobactam

2022
Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19).
    The Journal of antimicrobial chemotherapy, 2022, 09-30, Volume: 77, Issue:10

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Cyclooctanes; Enterobacteriaceae; Gram-Negative Bacteria; Hydrazines; Lactams; Microbial Sensitivity Tests; Piperidines; Pseudomonas aeruginosa; Tazobactam

2022
High-risk lineages among extended-spectrum β-lactamase-producing Escherichia coli from extraintestinal infections in Maputo Central Hospital, Mozambique.
    International journal of antimicrobial agents, 2022, Volume: 60, Issue:4

    Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefotaxime; Ceftazidime; Ciprofloxacin; Clavulanic Acid; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Extraintestinal Pathogenic Escherichia coli; Gentamicins; Hospitals; Humans; Iron; Mozambique; Piperacillin; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination

2022
Analysis of a novel class A β-lactamase OKP-B-6 of Klebsiella quasipneumoniae: structural characterisation and interaction with commercially available drugs.
    Memorias do Instituto Oswaldo Cruz, 2022, Volume: 117

    Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Klebsiella; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Docking Simulation; Sulbactam; Sulfhydryl Reagents; Tazobactam

2022
Computational and data mining studies to understand the distribution and dynamics of Temoneria (TEM) β-lactamase and their interaction with β-lactam and β-lactamase inhibitors.
    Environmental pollution (Barking, Essex : 1987), 2022, Dec-01, Volume: 314

    Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Data Mining; Molecular Docking Simulation; Monobactams; Penicillins; Tazobactam

2022
Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa.
    Scientific reports, 2022, 10-07, Volume: 12, Issue:1

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Lactams; Microbial Sensitivity Tests; Monobactams; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2022
Drug resistance characteristics and molecular typing of Escherichia coli isolates from neonates in class A tertiary hospitals: A multicentre study across China.
    The Journal of infection, 2022, Volume: 85, Issue:5

    Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Carbapenems; Cefotaxime; Child; Ciprofloxacin; Doxycycline; Drug Resistance; Escherichia coli; Escherichia coli Infections; Female; Humans; Infant, Newborn; Microbial Sensitivity Tests; Multilocus Sequence Typing; Piperacillin; Pregnancy; Tazobactam; Tertiary Care Centers; Trimethoprim, Sulfamethoxazole Drug Combination

2022
How to Manage Pseudomonas aeruginosa Infections.
    Advances in experimental medicine and biology, 2022, Volume: 1386

    Topics: Anti-Bacterial Agents; Carbapenems; Colistin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Fosfomycin; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2022
Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB.
    Blood advances, 2023, 05-09, Volume: 7, Issue:9

    Topics: Anti-Infective Agents; Carbapenems; Cohort Studies; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Neutropenia; Piperacillin; Retrospective Studies; Tazobactam; Transplantation, Homologous

2023
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
    The Journal of antimicrobial chemotherapy, 2022, 12-23, Volume: 78, Issue:1

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2022
Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients.
    Antimicrobial resistance and infection control, 2022, 11-30, Volume: 11, Issue:1

    Topics: Carbapenems; Cefepime; Ceftazidime; Phenotype; Pseudomonas aeruginosa; Tazobactam

2022
Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent.
    Clinical therapeutics, 2023, Volume: 45, Issue:1

    Topics: Anti-Bacterial Agents; Carbapenems; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Mitomycin; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tazobactam

2023
[Relationship of Hypervirulent Capsular Genotypes of Klebsiella pneumoniae with Antibiotic Susceptibility and Beta-Lactamase Genes].
    Mikrobiyoloji bulteni, 2023, Volume: 57, Issue:1

    Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Clavulanic Acid; Colistin; Drug Resistance, Bacterial; Genotype; Klebsiella pneumoniae; Microbial Sensitivity Tests; Piperacillin; Tazobactam

2023
Evaluation of in-vitro susceptibility of ß-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil.
    Revista da Sociedade Brasileira de Medicina Tropical, 2023, Volume: 56

    Topics: Anti-Bacterial Agents; beta-Lactamases; Brazil; Carbapenems; Ceftazidime; Cephalosporins; Drug Combinations; Gram-Negative Bacteria; Hospitals, General; Klebsiella pneumoniae; Lactams; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Tazobactam

2023
Evaluation of three commercial methods of susceptibility testing for ceftolozane/tazobactam against carbapenem-resistant Pseudomonas aeruginosa.
    Enfermedades infecciosas y microbiologia clinica (English ed.), 2023, Volume: 41, Issue:10

    Topics: Anti-Bacterial Agents; Carbapenems; Cross Infection; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2023
Prevalence of Multidrug Resistant Pseudomonas aeruginosa Isolated from Clinical Specimens in Tertiary Care Hospital.
    Journal of Nepal Health Research Council, 2023, Mar-07, Volume: 20, Issue:3

    Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cross-Sectional Studies; Humans; Microbial Sensitivity Tests; Nepal; Piperacillin; Prevalence; Pseudomonas aeruginosa; Tazobactam; Tertiary Care Centers

2023
Satisfactory In Vitro Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant
    Medicina (Kaunas, Lithuania), 2023, Mar-07, Volume: 59, Issue:3

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Klebsiella pneumoniae; Pseudomonas aeruginosa; Tazobactam

2023
Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020.
    Journal of global antimicrobial resistance, 2023, Volume: 33

    Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Ertapenem; Escherichia coli; Hong Kong; Humans; Imipenem; Intensive Care Units; Meropenem; Pseudomonas aeruginosa; Tazobactam

2023
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveil
    International journal of antimicrobial agents, 2023, Volume: 62, Issue:2

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Doripenem; Humans; Imipenem; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2023
Susceptibility of ceftolozane/tazobactam against multidrug-resistant and carbapenem-resistant Pseudomonas aeruginosa.
    The new microbiologica, 2023, Volume: 46, Issue:2

    Topics: Anti-Bacterial Agents; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2023
Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan-SMART 2012-2021.
    Journal of global antimicrobial resistance, 2023, Volume: 34

    Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Enterobacteriaceae; Humans; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Taiwan; Tazobactam

2023